BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12556205)

  • 21. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?
    Olsson A; Manzl C; Strasser A; Villunger A
    Cell Death Differ; 2007 Sep; 14(9):1561-75. PubMed ID: 17627286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of p53-mediated cell-cycle arrest, senescence and apoptosis promotes genomic instability and premature aging.
    Li T; Liu X; Jiang L; Manfredi J; Zha S; Gu W
    Oncotarget; 2016 Mar; 7(11):11838-49. PubMed ID: 26943586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-translational modifications of p53 tumor suppressor: determinants of its functional targets.
    Taira N; Yoshida K
    Histol Histopathol; 2012 Apr; 27(4):437-43. PubMed ID: 22374721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells.
    Donninger H; Binder A; Bohm L; Parker MI
    Biol Chem; 2008 Jan; 389(1):57-67. PubMed ID: 18095870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apoptosis, cancer and the p53 tumour suppressor gene.
    Lee JM; Bernstein A
    Cancer Metastasis Rev; 1995 Jun; 14(2):149-61. PubMed ID: 7554031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crippling p53 activities via knock-in mutations in mouse models.
    Iwakuma T; Lozano G
    Oncogene; 2007 Apr; 26(15):2177-84. PubMed ID: 17401426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53: an overview of over two decades of study.
    Cheah PL; Looi LM
    Malays J Pathol; 2001 Jun; 23(1):9-16. PubMed ID: 16329542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of p53-target genes in human cancer.
    Tokino T; Nakamura Y
    Crit Rev Oncol Hematol; 2000 Jan; 33(1):1-6. PubMed ID: 10714958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
    Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG
    Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 and human cancers.
    Lane DP
    Br Med Bull; 1994 Jul; 50(3):582-99. PubMed ID: 7987642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.
    Gu J; Kawai H; Wiederschain D; Yuan ZM
    Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53: balancing tumour suppression and implications for the clinic.
    Buganim Y; Rotter V
    Eur J Cancer; 2009 Sep; 45 Suppl 1():217-34. PubMed ID: 19775621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.
    Rowan S; Ludwig RL; Haupt Y; Bates S; Lu X; Oren M; Vousden KH
    EMBO J; 1996 Feb; 15(4):827-38. PubMed ID: 8631304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations in the p53 and SCID genes cooperate in tumorigenesis.
    Nacht M; Strasser A; Chan YR; Harris AW; Schlissel M; Bronson RT; Jacks T
    Genes Dev; 1996 Aug; 10(16):2055-66. PubMed ID: 8769648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 mutant mice that display early ageing-associated phenotypes.
    Tyner SD; Venkatachalam S; Choi J; Jones S; Ghebranious N; Igelmann H; Lu X; Soron G; Cooper B; Brayton C; Park SH; Thompson T; Karsenty G; Bradley A; Donehower LA
    Nature; 2002 Jan; 415(6867):45-53. PubMed ID: 11780111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 mutation heterogeneity in cancer.
    Soussi T; Lozano G
    Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
    Liu WL; Midgley C; Stephen C; Saville M; Lane DP
    J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promyelocytic leukemia protein is required for gain of function by mutant p53.
    Haupt S; di Agostino S; Mizrahi I; Alsheich-Bartok O; Voorhoeve M; Damalas A; Blandino G; Haupt Y
    Cancer Res; 2009 Jun; 69(11):4818-26. PubMed ID: 19487292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TP53 tumor-suppressor gene and human carcinogenesis.
    Basset-Séguin N; Molès JP; Mils V; Dereure O; Guilhou JJ
    Exp Dermatol; 1993 Jun; 2(3):99-105. PubMed ID: 8162331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Death squads enlisted by the tumour suppressor p53.
    Michalak E; Villunger A; Erlacher M; Strasser A
    Biochem Biophys Res Commun; 2005 Jun; 331(3):786-98. PubMed ID: 15865934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.